CD44 variations could serve as more reliable biomarkers for advanced or chemo-resistant TC compared to conventional markers like thyroglobulin, as they reflect the tumor’s ability to evade apoptosis, maintain stem-like features, and efflux drugs, factors central to MDR [154]. This evidence concerns the gene CD44 and neoplasm.